Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Biotechnol. 2001 Nov;19(11):1035-41.

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.

Author information

  • 1Canji, Inc. 3525 John Hopkins Court, San Diego, CA 92121, USA. murali.ramachandra@canji.com

Abstract

Replicating adenoviruses may prove to be effective anticancer agents if they can be engineered to selectively destroy tumor cells. We have constructed a virus (01/PEME) containing a novel regulatory circuit in which p53-dependent expression of an antagonist of the E2F transcription factor inhibits viral replication in normal cells. In tumor cells, however, the combination of p53 pathway defects and deregulated E2F allows replication of 01/PEME at near wild-type levels. The re-engineered virus also showed significantly enhanced efficacy compared with extensively studied E1b-deleted viruses such as dl1520 in human xenograft tumor models.

Comment in

PMID:
11689848
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk